Asia Pacific Pulmonary Arterial Hypertension Market Size & Outlook
Asia Pacific pulmonary arterial hypertension market, 2018-2030 (US$M)
Related Markets
Asia Pacific pulmonary arterial hypertension market highlights
- The Asia Pacific pulmonary arterial hypertension market generated a revenue of USD 952.0 million in 2023.
- The market is expected to grow at a CAGR of 6.7% from 2024 to 2030.
- In terms of segment, prostacyclin and prostacyclin analogs was the largest revenue generating drug class in 2023.
- SGC Stimulators is the most lucrative drug class segment registering the fastest growth during the forecast period.
- Country-wise, South Korea is expected to register the highest CAGR from 2024 to 2030.
Asia Pacific data book summary
| Market revenue in 2023 | USD 952.0 million |
| Market revenue in 2030 | USD 1,501.9 million |
| Growth rate | 6.7% (CAGR from 2023 to 2030) |
| Largest segment | Prostacyclin and prostacyclin analogs |
| Fastest growing segment | SGC Stimulators |
| Historical data covered | 2018 - 2022 |
| Base year for estimation | 2023 |
| Forecast period covered | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Endothelin Receptor Antagonists (ERAs), PDE-5 Inhibitors, Prostacyclin and Prostacyclin Analogs, SGC Stimulators |
| Key market players worldwide | United Therapeutics Corp, Bayer AG, Gilead Sciences Inc, Johnson & Johnson, Viatris Inc, GlaxoSmithKline, Sandoz Group AG ADR, Lupin, Sun Pharmaceutical Industries, Teva Pharmaceutical Industries Ltd |
Other key industry trends
- In terms of revenue, Asia Pacific region accounted for 12.9% of the global pulmonary arterial hypertension market in 2023.
- Globally, North America is projected to lead the regional market in terms of revenue in 2030.
- Asia Pacific is the fastest growing regional market and is projected to reach USD 1,501.9 million by 2030.
Prostacyclin and prostacyclin analogs was the largest segment with a revenue share of 47.46% in 2023. Horizon Databook has segmented the Asia Pacific pulmonary arterial hypertension market based on endothelin receptor antagonists (eras), pde-5 inhibitors, prostacyclin and prostacyclin analogs, sgc stimulators covering the revenue growth of each sub-segment from 2018 to 2030.
Asia Pacific is likely to witness lucrative growth over the estimated period owing to increasing government initiatives and better healthcare infrastructure. Moreover, economic developments in countries such as India and China are expected to help market growth.
High population and low per capita income led to rise in demand for affordable treatment options. MNCs are focused on investing in developing countries such as India and China. Thus, many partnerships and strategic alliances are being undertaken by organizations in this region.
Rapid development in the Asia Pacific region, high population, and improving healthcare systems are anticipated to aid in lucrative growth of the region. Economic development in countries such as India and China are supporting growth of this region. Moreover, high incidence of diseases such as HIV, which are responsible for development of PAH, aid growth of this regional market.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Pulmonary Arterial Hypertension Market Scope
Pulmonary Arterial Hypertension Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
Asia Pacific pulmonary arterial hypertension market size, by country, 2018-2030 (US$M)
Asia Pacific Pulmonary Arterial Hypertension Market Outlook Share, 2023 & 2030 (US$M)
Related regional statistics
No records
No related regions found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
